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U.S. Army Medical Research and Materiel Command
The year 1 aims were primarily concerned with collecting shRNA constructs so that a small number that have inhibitory effects on breast cancer progression in vivo models could be identified. In the past year, we have a collated a set of encoded hairpins targeting genes overexpressed in ErbB-2 positive breast tumors. We have also spent considerable effort testing the compatibility of several assays for cellular correlates of tumorigenicty with high throughput gene transfer. To date, we have retrieved 65 shRNA constructs targeting 51 of the genes overexpressed ErbB2-positive breast cancer cells and tested them for effects on cell proliferation in a screen in BT474 cells. Somewhat surprisingly, almost 35% of the hairpins used in the screening cause similar or greater reduction of cell proliferation than ErbB-2 shRNA controls. Although several of the genes whose decreased expression compromises proliferation rate have been shown to play a role in tumor cell growth, it is clear that these constructs must now be tested for effects on normal cells, i.e. human mammary epithelial cells (HMECs), to assess whether these represent pathways that are required specifically for tumor cell proliferation.
Introduction
The recent explosion of genome sequences and bioinformatic data has changed the nature of mammalian genetics. Systematic investigation of expression patterns of thousands of genes in breast tumors using cDNA microarrays and serial analysis of gene expression has yielded a long list of genes whose increased activity is correlated with the occurrence of breast cancer (1) (2) (3) (4) . In notable cases, associations between gene expression levels and clinical outcome have been determined. In most cases, however, the information is only correlative and serves as a rough guide to genes that might positively influence some aspect of breast cancer.
We are working towards identifying which of the nearly 100 genes typically overexpressed in ErbB-2 positive breast tumors are important for the survival and aggressiveness of breast cancer cells. Our approach makes use of DNA-encoded short hairpin RNAs that elicit an RNA interference silencing of the overexpressed genes.
Using high throughput methodologies, we have constructed a library of sequenceverified hairpins that target most human genes (5) . Constructs from the library are being used for the systematic validation of breast cancer molecular profiling data in ErbB-2 positive BT 474 cells. Cellular correlates of tumorigenicity such as proliferation rate, resistance to apoptosis and anchorage independent growth are assayed in cells containing shRNA constructs that target overexpressed genes. The overall objective of this proposal is to identify hairpins that have inhibitory effects on breast cancer progression in in vivo models.
This would add to our understanding of the genes involved in breast cancer and identify their products as potential small molecule therapeutic targets. It would also pave the way for testing of the hairpins that we identify as gene therapeutics.
The underlying hypothesis of this proposal is that functional genomic screening with DNA-encoded RNA interference can identify those genes that breast cancer cells actually rely on to cause cancer. We will systematically target the most commonly overexpressed genes in breast cancer cells especially those that are overexpressed in association with ErbB-2 amplification. Many of these genes are likely to be involved in granting some sort of survival advantage to these cells during cancer progression. Silencing key genes in this group should reverse the cancer phenotype. In this way, we expect to gain insights into which genes are actually required by breast cancer cells to cause cancer and would therefore make excellent therapeutic targets. Moreover, it may contribute directly to the development of gene-based therapeutics by identifying short hairpin RNAs that could someday be used clinically.
Body
There has been good progress on the proposed work for completion by the end of twelve months. The major goal of this time period as set forth in the Statement of Work was: Creation of a set of encoded hairpins targeting genes overexpressed in ErbB-2 positive breast tumors. This goal has been met.
An important first step was recruiting a postdoctoral fellow to work on the project, Dr. Antonis Kourtidis joined the lab in January. Antonis has recently received his PhD in molecular biology from the Aristotle University of Thessaloniki in Greece. He has been responsible for performing most of the work on the project to date.
Months 1-12 of the proposal were to be spent in the creation of a set of encoded hairpins that targeted those genes commonly overexpressed in ErbB-2 positive breast tumors.
We had planned to make use of a library of over 20,000 sequence-verified hairpins that we had constructed. This library targeted approximately 10,000 human genes. Included were those genes which encoded all of the protein classes that are viewed to be accessible to medicinal chemistry. More importantly, the majority of sequences identified in ErbB-2 positive breast cancer molecular profiling experiments were also represented in the library. Although the original plan was to collect these from an existing short hairpin RNA library and synthesize any missing constructs for genes, advances in RNAi technology simplified this process. A second generation library was constructed in a vector that produces more infective viral particles and expresses short hairpin RNAs with better silencing properties. This library is available through a commercial vendor. As a developer of the original shRNA library detailed in the proposal, I have received the entire library targeting virtually every gene in the human library at cost from the supplier. Although this resource became available early this year, it has simplified assembling a sublibrary of shRNAs targeting overexpressed genes.
The year 1 aims were primarily concerned with collecting shRNA constructs so that a small number that have inhibitory effects on breast cancer progression in vivo models could be identified. This would add to our understanding of the genes involved in breast cancer and identify their products as potential small molecule therapeutic targets. It would also pave the way for testing of the hairpins that we identify as gene therapeutics. The accession numbers corresponding to the genes overexpressed in erb-B2 positive breast cancer are given in Table 1 . A complete listing of the constructs is given in the appendix. NM_000125   NM_001982  NM_003651  NM_004901  NM_005574  NM_014399 NM_001903  NM_000212  NM_002014  NM_003710 NM_004933  NM_005765  NM_016016 NM_052886   NM_000224  NM_002203  NM_003909 NM_005005  NM_005885  NM_017802  NM_002795  NM_000419  NM_002266  NM_004265  NM_005015 NM_005930  NM_018728  NM080861   NM_000442  NM_002317  NM_004448  NM_005030 NM_006148  NM_018979  NM_004893  NM_000595  NM_002353  NM_004483 NM_005079 NM006265  NM_020974  NM_178516  NM_001026  NM_002411  NM_004496  NM_005213 NM_006276  NM_021724 NM_005570   NM_001216 NM_002417  NM_004643  NM_005228  NM_006432  NM_021980 NM_203365  NM_001311  NM_002585  NM_004747  NM_005310  NM_006601  NM_024101  NM_012229   NM_001408  NM_002758  NM_004774  NM_005324  NM_006726  NM_032308 NM_033419  NM_001429 NM_002791 NM_004888 NM_005556 NM_007067 NM_033418 Table 1 . Accession numbers corresponding to the genes overexpressed in erb-B2 positive breast cancer
In the past year, we have spent considerable effort testing the compatibility of several assays for cellular correlates of tumorigenicty with high throughput gene transfer. Among these are standard soft agar assays, DAPI staining to quantify apoptotic nuclei, Cyquant assays, Rb and E2F luciferase-based reporter cell cycle progression assays, Alamar blue proliferation stains and live cell counts. Although the assays are straightforward, most were insufficiently robust for large scale analysis. Instead we have found that using Alamar blue (Biosource) reduction that is normalized to GFP transfection efficiency to measure shRNA containing cell proliferation is the most workable assay in high throughput. This assay is by far the most robust.
To date, we have retrieved 65 shRNA constructs targeting 51 of the genes overexpressed ErbB2-positive breast cancer cells and tested them for effects on cell proliferation in a screen in BT474 cells. A non-specific hairpin construct targeting the firefly luciferase gene was used as a negative control. Purified DNA for each construct was prepared and used to transiently transfect BT 474s in 96-well plates in triplicate. Transfection efficiency was monitored by co-transfecting with a plasmid construct expressing green fluorescent protein (EGFP). After three days, the abilty of the shRNA to decrease cell viability was determined by quantifying proliferation using Alamar blue (Biosource) reduction that had been normalized to GFP fluorescence. We have found that this is a relatively rapid and reliable method for quantification of proliferation changes.
Our results showed that hairpins targeting genes with known impact on breast cancer, such as ErbB-2, ErbB-3 and EGFR, resulted in reduction of proliferation up to 23% compared to the non-specific hairpin construct (Fig. 1) . Somewhat surprisingly, almost 35% of the hairpins used in the screening resulted in similar or greater reduction of cell proliferation when compared to the ErbB-2 shRNA controls (Fig. 1 ). Although several of the genes whose decreased expression compromises proliferation rate have been shown to play a role in tumor cell growth, it is clear that these constructs must now be tested for effects on normal cells, i.e. human mammary epithelial cells (N-MECs), to assess whether these represent pathways that are required specifically for tumor cell proliferation. In addition to well known targets, it was expected that this sort of approach would reveal novel pathways. Although the results are still at an early stage, we are optimistic. For example, hairpins targeting several HSP70s, the peroxisome proliferator activated receptor (PPAR) binding protein (PPARBP, PBP) and the nuclear receptor 1s, D1 (NR1 D1, RevErba) all resulted in reduced proliferation (Fig. 1) . Cell proliferation was reduced both by a hairpin targeting the major heat-inducible HSPA1A gene and by three different hairpins targeting the also inducible HSPA6 (Fig. 1) . Recently, RNAi against another member of the HSP70 family, the moderately-expressed, testis associated, HSP70-2 gene, also resulted in attenuation proliferation of the cells (6) . The role of the HSP70 genes in breast cancer cell proliferation, metastasis, poor differentiation, and drug resistance is well established (7), but the downstream targets of the HSP70 genes during cancer development have not been extensively studied yet. It has been suggested by a limited number of studies that these two genes may be functionally related to HSP70. PBP is a co-activator of the PPAR receptors, which some of their ligands have been shown to induce HSP70 expression (8, 9) . PPARoA overexpression in rat hydrocephalus cells was concurrent to HSP70 overexpression (10) . An indirect link could be also that of the HSP90 stress protein, which binds to the HSP70 during stress response, but it also acts as a repressor of the PPARa, without the biological consequences being clarified yet (11) . The N R1 D1 /RevErba receptor has been found to be induced by the activated PPARy during adipocyte differentiation of 3T3-L1 cells (12) . It would be very interesting to examine all the possible functional links between the above genes during breast cancer progression. Under this point of view, it is also interesting that PBP was found to interact with the estrogen receptor alpha (ERa), serving as a co-activator in the ER signaling and therefore suspected to be involved in breast cell tumorigenicity (13) . In addition, there has also been shown that there is a regulatory link between NR1D1 and the NFKB pathway (14) .
On-going and future work:
Little is changed from the original proposal. Those constructs that target overexpressed
genes not yet tested for effects on proliferation will be tested in the proliferation assay. Constructs that are without effect on human mammary epithelial cells (HMECs) but that inhibit the growth of tumor cells will be tested in mouse models as proposed. In addition, the available hairpin constructs will be packaged in amphotropic retroviral packaging cells. Retroviral supernatants will be used to infect BT474 cells. Infected populations will be monitored for phenotypic changes related to tumorigenicity that are not suited for high throughput analysis. These include resistance to apoptosis and anchorage independent.
Although as proposed, it was not our intent to carry out a detailed investigation of the phenotypes that result from expression of a particular hairpin. It should be clear that the information gained in this investigation can hopefully be used in further studies. It is possible, for example, to carry out a functional genomic analysis using RNAi in breast cancer cell lines of potential relationships between the HSP70, PPARBP-PBP and NRID1-RevErba genes. In this way we can study in depth the pathways that are implicated as well as their relationship to the breast tumor progression. The recent explosion of genome sequences and bioinformatic data has changed the nature of mammalian genetics. Systematic investigation of expression patterns of thousands of genes in breast tumors using cDNA microarrays and serial analysis of gene expression has yielded a long list of genes whose increased activity is correlated with the occurrence of breast cancer. In notable cases, associations between gene expression levels and clinical outcome have been determined. In most cases, however, the information is only correlative and serves as a rough guide to genes that might positively influence some aspect of breast cancer.
We are working towards identifying which of the nearly 100 genes typically overexpressed in ErbB-2 positive breast tumors are important for the survival and aggressiveness of breast cancer cells. Our approach makes use of DNA-encoded short hairpin RNAs that elicit an RNA interference silencing of the overexpressed genes. Using high throughput methodologies, we have constructed a library of over 20,000 sequence-verified hairpins. These library constructs target approximately 10,000 human genes which encode all of the protein classes that are viewed to be accessible to medicinal chemistry. More importantly, the majority of sequences identified in ErbB-2 positive breast cancer molecular profiling experiments are also represented in the library. Constructs from the library are being used for the systematic validation of breast cancer molecular profiling data in ErbB-2 positive BT 474 cells. Cellular correlates of tumorigenicity such as proliferation rate, resistance to apoptosis and anchorage independent growth are assayed in cells containing shRNA constructs that target overexpressed genes.
The overall objective of this proposal is to identify hairpins that have inhibitory effects on breast cancer progression in in vivo models. This would add to our understanding of the genes involved in breast cancer and identify their products as potential small molecule therapeutic targets. It would also pave the way for testing of the hairpins that we identify as gene therapeutics. Development of cell lines, tissue or serum repositories:
As was proposed, the collection of shRNA constructs targeting overexpressed genes that contribute to breast cancer tumorigenicity will undoubtedly be useful to many investigators and will be made available as soon as testing is complete.
Funding applied for based on work supported by this award:
None. With further progress it is hoped that sufficient data will be available for submission of an R01.
Employment or research opportunities applied for and/or received based on experience/training supported by this award:
This award enabled the PI and a post doctoral fellow to attend the Era of Hope Meeting in Philadelphia. Several potential collaborative projects were initiated at this meeting.
Conclusions
Year 1 of funding has resulted in the collation of a large set of constructs targeting genes overexpressed in ErbB-2 positive breast tumors. We have also developed a relatively rapid and reliable method for quantification of proliferation changes due to shRNA expression in cells. Using this we have identified approximately 30 genes that negatively impact the growth of Erb-B2 positive breast cancer cells.
Little has changed with respect to Year 2 Proposed Work. Those constructs not yet tested for effects on proliferation will be tested in the proliferation assay. All shRNA constructs that have tested positively will also be tested for similar effects in human mammary epithelial cells. Constructs that are without effect on HMECs but that inhibit the growth of tumor cells will be tested in mouse models as proposed. In addition, the available hairpin constructs will be packaged in amphotropic retroviral packaging cells. Retroviral supernatants will be used to infect BT474 cells. Infected populations will be monitored for phenotypic changes related to tumorigenic potential including apoptosis and growth in soft agar.
"So what?" one might ask.
Although we are still determining the effect that suppressing the expression of these genes has on the tumorigenicity of breast cancer cells, that we have identified a large number of RNAi constructs that inhibit breast tumor cell proliferation is encouraging. With further study it is hoped that this ultimately will add to our understanding of the genes encoding potential small molecule therapeutic targets in breast and other cancers. It should also pave the way for testing of the hairpins that we identify as gene therapeutics.
